Pondicherry Journal of Nursing

Register      Login

VOLUME 12 , ISSUE 1 ( January-March, 2019 ) > List of Articles


A Hybrid Closed-loop Insulin Delivery System for the Treatment of Type I Diabetes

E Finny Moses

Keywords : AI in blood sugar control, Artificial pancreas, Continuous glucose monitor, Hybrid closed-loop insulin, Synthetic pancreas

Citation Information : Moses EF. A Hybrid Closed-loop Insulin Delivery System for the Treatment of Type I Diabetes. 2019; 12 (1):25-27.

DOI: 10.5005/jp-journals-10084-12104

License: CC BY-NC 4.0

Published Online: 01-06-2019

Copyright Statement:  Copyright © 2019; The Author(s).


The hybrid closed-loop insulin delivery system serves as the world's first synthetic (artificial) pancreas. The hybrid closed-loop insulin delivery system will help the type I diabetes patients in controlling their insulin quantity in the body. This was approved in late 2017 by the Food and Drug Administration (FDA), which owns a neotechnology that enables to have a direct link between the device and insulin pump to even out blood glucose at an exceptional level. This technology switches the “open loop” system that needs patients to access their own information to calculate how much insulin has to be injected. Many type I diabetes mellitus (DM) patients demand this technology in 2019. Many experts also predict that a similar technology will hit community soon for the type II diabetes patients.

  1. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375(9733):2215–2222. DOI: 10.1016/S0140-6736(10)60484-9.
  2. Bourne RR, Stevens GA, White RA, Smith JL, Flaxman SR, Price H, et al. Causes of vision loss worldwide, 1990–2010: a systematic analysis. Lancet Glob Health 2013;1(6):e339–e349. DOI: 10.1016/S2214-109X(13)70113-X.
  3. Trevitt S, Simpson S, Wood A. Artificial pancreas device systems for the closed-loop control of type 1 diabetes: what systems are in development? J Diabetes Sci Technol 2016 May;10(3):714–723. DOI: 10.1177/1932296815617968.
  4. United States Renal Data System. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2014:188–210.
  5. Hanazaki K, Munekage M, Kitagawa H, Yatabe T, Munekage E, Shiga M, et al. Current topics in glycemic control by wearable artificial pancreas or bedside artificial pancreas with closed-loop system. J Artif Organs 2016 Sep;19(3):209–218. DOI: 10.1007/s10047-016-0904-y.
  6. Minimed 670G: a hybrid closed-loop insulin delivery system. Med Lett Drugs Ther 2016;58(1508):147–148.
  7. Iacovacci V, Ricotti L, Menciassi A, Dario P. The bioartificial pancreas (BAP): biological, chemical and engineering challenges. Biochem Pharmacol 2016;100:12–27. DOI: 10.1016/j.bcp.2015.08.107.
  8. Haidar A, Smaoui MR, Legault L, Rabasa-Lhoret R. The role of glucagon in the artificial pancreas. Lancet Diabetes Endocrinol 2016;4(6):476–479. DOI: 10.1016/S2213-8587(16) 30006-7.
  9. The pharmacology in type 1 diabetes: executive summary. Available from: http://www.canadianjournalofdiabetes.com/article/S1499-2671(13)00061-0/pdf, 2013. pp. S310–S311.
  10. Silver Spring (MD): U.S. Food and Drug Administration; 2016. Mini Med 670G system.
  11. Ly TT, Weinzimer SA, Maahs DM, Sherr JL, Roy A, Grosman B, et al. Automated hybrid closed-loop control with a proportional-integral-derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance. Pediatr Diabetes. 2016 May 18; Epub ahead of print.
  12. Kropff J, Devries JH. Continuous Glucose Monitoring, Future Products, and Update on Worldwide Artificial Pancreas Projects. Diabetes Technol Ther 2016 Feb;18(Supp 2):S253–S263. DOI: 10.1089/dia. 2015.0345.
  13. Oron T, Farfel A, Muller I, Miller S, Atlas E, Nimri R, et al. A remote monitoring system for artificial pancreas support is safe, reliable, and user-friendly. Diabetes Technol Ther 2016;18(Suppl 1): S93–S94.
  14. Thabit H, Tauschmann M, Allen JM, Leelarathna L, Hartnell S, Wilinska ME, et al. Home Use of an Artificial Beta Cell in Type 1 Diabetes. 2015 Nov 26;2129–2140.
  15. Fradkin JE, Wallace JA, Akolkar B, Rodgers GP. Type 1 Diabetes–Reaping the Rewards of a Targeted Research Investment. Diabetes 2016 Feb;65(2):307–313. DOI: 10.2337/db15-1030.
  16. Bell K. Medtronic's MiniMed 670G system approved by FDA for type 1 diabetes [Internet] First Word Medtech. Sep 28, 2016.
  17. Malek R, Davis SN. Novel Methods of Insulin Replacement: The Artificial Pancreas and Encapsulated Islets. Rev Recent Clin Trials 2016;11(2):106–123.
  18. Garg SK, Weinzimer SA, Tamborlane WV, Buckingham BA, Bode BW, Bailey TS, et al. Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes. Diabetes Technol Ther 2017 Mar;19(3):155–163. DOI: 10.1089/dia.2016.0421.
  19. Chatterjee S, Davies MJ. Current management of diabetes mellitus and future directions in care. Postgrad Med J 2015 Nov;91(1081): 612–621. DOI: 10.1136/postgradmedj-2014-133200.
  20. Rodbard D. Continuous glucose monitoring: a review of successes, challenges, and opportunities. Diabetes Technol Ther 2016 Feb;18(Suppl 2):S3–S13. DOI: 10.1089/dia.2015.0417.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.